Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

‘Big Shoes To Fill’: US FDA Commissioner Hahn’s Baptism By Fire

Executive Summary

Every new FDA commissioner faces a challenge earning credibility with Congress and the public, but in the context of COVID-19, Stephen Hahn has a double challenge of a public health crisis – and the ongoing prominence of his predecessor at the agency.

You may also be interested in...



US FDA Commissioner Hahn’s Star Turn: Baptism By Fire Turns Perilous

FDA Commissioner Stephen Hahn was added to the White House's pandemic task force as the outbreak grew, but he remained in a background role. That all changed the morning of 18 March, when President Trump tweeted: “I will be having a news conference today to discuss very important news from the FDA concerning the Chinese Virus!” A day later, Hahn was standing with Trump at the podium for the now-daily press briefings on Covid-19.

US FDA Commissioner Hahn’s Star Turn: Baptism By Fire Turns Perilous

Stephen Hahn’s low visibility period as the newly installed FDA commissioner comes to an abrupt end. Trump offers generous praise amid COVID-19 response – but how quickly might that change to blame?

US FDA Commissioner Tries To Allay Concerns About Inspection Postponements

Screenings at ports of entry may be modified, but the drug supply remains safe and secure, Stephen Hahn tells House Committee, arguing that other tools will allow for continued facility policing during the coronavirus outbreak even if the absence of inspections.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS141838

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel